SCREENING OR MONITORING | TYPE OF OAT | ENROLMENT IN MEDICAL HOME | PHYSICIAN PRESCRIBING VOLUME | ||||
---|---|---|---|---|---|---|---|
METHADONE | BUPRENORPHINE | NOT ENROLLED | ENROLLED IN NON–TEAM-BASED HOME | ENROLLED IN TEAM-BASED HOME | LOW | HIGH | |
Cervical cancer screening | |||||||
• Eligible, n | 7398 | 425 | 4215 | 2577 | 1031 | 1619 | 6204 |
• Screened, n (%) | 3552 (48.0)* | 260 (61.2) | 1924 (45.6) | 1302 (50.5)* | 586 (56.8)* | 824 (50.9) | 2988 (48.2) |
• Adjusted OR (95% CI)† | Reference | 1.67 (1.35–2.07) | Reference | 1.19 (1.08–1.32) | 1.48 (1.29–1.71) | Reference | 0.85 (0.76–0.96) |
Breast cancer screening | |||||||
• Eligible, n | 1095 | 90 | 638 | 410 | 137 | 304 | 881 |
• Screened, n (%) | 249 (22.7)* | 27 (30.0) | 144 (22.6) | 93 (22.7) | 39 (28.5)* | 86 (28.3) | 190 (21.6)* |
• Adjusted OR (95% CI)† | Reference | 1.04 (0.58–1.87) | Reference | 0.95 (0.70–1.29) | 1.30 (0.85–1.99) | Reference | 0.71 (0.52–0.97) |
Colorectal cancer screening | |||||||
• Eligible, n | 3413 | 231 | 2013 | 1243 | 388 | 1036 | 2608 |
• Screened, n (%) | 1069 (31.3)* | 115 (49.8) | 563 (28.0) | 456 (36.7)* | 165 (42.5)* | 371 (35.8) | 813 (31.2)* |
• Adjusted OR (95% CI)† | Reference | 1.84 (1.35–2.49) | Reference | 1.38 (1.19–1.62) | 1.74 (1.38–2.19) | Reference | 0.84 (0.71–0.98) |
Optimal diabetes monitoring | |||||||
• Eligible, n | 1332 | 75 | 713 | 527 | 164 | 371 | 1036 |
• Monitored, n (%) | 148 (11.1)* | 16 (21.3) | 71 (10.0) | 70 (13.3)* | 23 (14.0)* | 41 (11.1) | 123 (11.9) |
• Adjusted OR (95% CI)† | Reference | 2.20 (1.15–4.19) | Reference | 1.39 (0.97–2.00) | 1.46 (0.87–2.45) | Reference | 1.21 (0.82–1.80) |
COPD—chronic obstructive pulmonary disease, OAT—opioid agonist treatment, OR—odds ratio.
↵* Indicates standardized difference > 0.10 compared with the reference group.
↵† Adjusted for age, sex (where appropriate), income quintile, presence of a psychotic disorder, COPD, physician clinic visits, type of OAT, enrolment in a medical home, volume of prescriber’s practice, and new-OAT-user status.